Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | LIPC | P11150 | 3/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | SNCA | P37840 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031653 | 0.85 | MGAM (0.48) | PIK3CAMTORMETKMT2AMEN1 | |
| SCHEMBL30032369 | 0.84 | ALDH1A1 (0.46) | MTORLIPCLIPGSNCANPC1 | |
| Hydrochloric Acid SCHEMBL30031147 | 0.76 | S1PR1 (0.48) | METLRRK2S1PR1 | |
| SCHEMBL646187 | 0.73 | DGAT1 (0.59) | KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL30031212 | 0.72 | NR1H2 (0.47) | PIK3CAMET | |
| SCHEMBL31227461 | 0.70 | RARB (0.48) | NPC1RAB9AS1PR1 | |
| SCHEMBL15594549 | 0.70 | MET (0.44) | PIK3CAMTORMETKMT2ANPC1 | |
| SCHEMBL31227469 | 0.69 | GSK3B (0.39) | ALDH1A1 | |
| SCHEMBL30032460 | 0.69 | KDM4E (0.58) | MTORKMT2AMEN1NPC1RAB9A | |
| SCHEMBL642910 | 0.69 | CES2 (0.61) | KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | NR1H2, NR1H3, NR1H4 | PIK3CA 651/4885MTOR 2622/4885LIPC 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.